LY3214996

LY3214996 (CAS No.: 1951483-29-6) is a potent and highly selective small-molecule inhibitor of extracellular signal-regulated kinases ERK1 and ERK2, key downstream effectors of the MAPK signaling cascade that regulate cell proliferation, differentiation, and survival. By directly inhibiting ERK1/2 enzymatic activity, LY3214996 effectively suppresses downstream phosphorylation events, including inhibition of p-RSK1, particularly in cancer cell lines harboring activating mutations in MAPK pathway components such as BRAF and RAS. In biochemical and cellular assays, it demonstrates strong inhibitory activity in the low nanomolar range, and it significantly reduces tumor cell proliferation in vitro across multiple oncogenic backgrounds, including B-RAF-, N-Ras-, and K-Ras-driven models. In vivo, LY3214996 exhibits robust antitumor efficacy in xenograft and patient-derived tumor models of melanoma, colorectal, lung, and pancreatic cancers with MAPK pathway alterations, supporting its utility as a research tool for investigating ERK-dependent signaling and therapeutic resistance mechanisms. This compound is widely applied in oncology research and drug discovery for pathway validation, target engagement studies, and evaluation of combination strategies, with experimental concentrations or dosing regimens varying according to specific model systems and study objectives.